Scientists identify possible target for prevention and treatment of pneumonia

Researchers at Children’s Hospital of Pittsburgh of UPMC have identified a key protein target that may be a crucial factor in the development of a vaccine to prevent and new therapies to treat pneumonia, the leading killer of children worldwide.

Research led by Jay K. Kolls, MD, chief of the Division of Pediatric Pulmonary Medicine, Allergy and Immunology at Children’s, identified for the first time the importance of a protein known as interleukin 22 (IL-22) in the immune response to a strain of bacterial pneumonia. In the laboratory, the researchers were able to effectively treat mice with pneumonia by using purified IL-22.

Results of the study are published in the February online issue of Nature Medicine.

“Currently there is no vaccine that covers all kinds of pneumonia and antibiotic treatment is sometimes limited by antibiotic resistance. As acute respiratory infections are the no. 1 killer of children in the world, progress in the development of novel vaccines or new, more effective treatments is critical,” said Dr. Kolls, the Neils K. Jerne Professor of Pediatrics and Immunology at the University of Pittsburgh School of Medicine. “Our results raise the possibility of developing new protein-based therapies using IL-22 to limit or prevent pneumonia.”

Pneumonia causes almost one in five deaths in children under age 5 worldwide – more than 2 million children each year, according to the World Health Organization. It kills more children than any other disease – more than AIDS and malaria combined.

IL-22 and interleukin 17A (IL-17A) are produced by a recently discovered lineage of cells known as T Helper Type 17 (Th17). Children’s researchers found evidence that the Th17 cell lineage and its cytokines IL-22 and IL-17A have evolved to promote host defense against certain infections in the lung caused by extracellular pathogens.

This is an important discovery because the Children’s research team proposes that by stimulating the Th17 arm of the immune system, they can more efficiently treat bacterial pneumonia. Furthermore, the researchers propose that Th17 is a less critical pathway for intracellular bacteria such as those that cause listeria and tuberculosis – thus raising the potential to target this pathway in diseases of chronic inflammation such as rheumatoid arthritis or inflammatory bowel disease without increasing susceptibility to these intracellaulr pathogens.

Dr. Kolls' laboratory investigates mechanisms of lung host defenses in normal and immunocompromised hosts as well as lung immunology in disease such as cystic fibrosis and asthma. Additional research interests of Dr. Kolls include gene therapy, lung immunology, lung host defenses, tumor necrosis factor, pneumocytis carinii pneumonia, ethanol, gene expression, polymerase chain reaction and molecular biology.

Source: Children's Hospital of Pittsburgh

Related stories:

Liver donor's family, recipient unite online
(AP) -- They were precocious toddlers, both blond-haired and blue-eyed, separated by a thousand miles between Miami and a small Kentucky town.
Despite vaccine, public should not get complacent about pneumococcal disease
Although the childhood pneumococcal conjugate vaccine has been a boon in reducing the incidence invasive pneumococcal disease (IPD), the public and the medical community must not get complacent, as non-vaccine strains, some resistant to antibiotics, are on the rise, say scientists at a meeting today in Boston.
Widespread airbag use could result in dramatic cost savings for US trauma centers
According to research published in the May issue of the Journal of the American College of Surgeons, the new generation of airbags not only helps protect motor vehicle collision (MVC) victims from injury and death, but also are associated with dramatic cost saving to trauma centers. The study shows that the deployment of airbags in MVCs, particularly in conjunction with the use of a seatbelt, significantly reduce injuries to the brain, face, spine and chest; as well as lower in-hospital mortality rates, injury severity and hospital-acquired infections for MVC victims.
Study suggests sick children should be tranferred to specialty hospitals sooner
Critically ill children admitted to the pediatric intensive care units of regional medical centers from smaller hospitals are sicker than those admitted directly from those centers' own emergency rooms, a study by pediatric critical care physicians at UC Davis Children's Hospital has found.
How will childhood pneumonia change if vaccine campaigns are a success?
In developing countries, two bacteria, pneumococcus and Hib, are the dominant causes of severe pneumonia in children.
How much progress has there been in vaccinating against Hib in the Americas?
The bacterium Haemophilus influenzae type b (Hib) causes at least 3 million cases of severe disease each year, and about 400,000 children die annually due to pneumonia or meningitis caused by Hib.
Physicist John Wheeler, Einstein collaborator, dead at 96
US physicist John Wheeler, one of Albert Einstein's last collaborators who helped build the atomic bomb and gave black holes their name, died at the weekend, his family said. He was 96.
Community-acquired staph pneumonia appears more common, including MRSA
Preliminary research from the Centers for Disease Control and Prevention (CDC) suggests that community acquired pneumonia (CAP) caused by the Staphylococcus aureus bacterium may be more common than originally suspected, including that caused by antibiotic resistant strains. Researchers report their findings today (March 19) at the 2008 International Conference on Emerging Infectious Diseases in Atlanta, Georgia.

News discussion:

Medicine & Health news